Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4147-4152

  Cammett, Anna Maria ^a   MacGregor, Thomas R ^a   Wruck, Jan M ^a   Felizarta, Franco ^a   Miailhes, Patrick ^a   Mallolas, Josep ^a   Piliero, Peter J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYNEVIRAPINE; 2 HYDROXYNEVIRAPINE; 3 HYDROXYNEVIRAPINE; 4 CARBOXYNEVIRAPINE; 8 HYDROXYNEVIRAPINE; ANTIRETROVIRUS AGENT; NEVIRAPINE; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLITE; MIXED INFECTION; PRIORITY JOURNAL; SCORING SYSTEM; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70349337803     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00460-09     Document Type: Article

References (16)

1. Barreiro, P., S. Rodriguez-Novoa, P. Labarga, A. Ruiz, I. Jimenez-Nacher, L. Martin-Carbonero, J. Gonzalez-Lahoz, and V. Soriano. 2007. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J. Infect. Dis. 195:973-979.
2. Berenguer, J., J. M. Bellon, P. Miralles, E. Alvarez, I. Castillo, J. Cosin, J. C. Lopez, M. Sanchez Conde, B. Padilla, and S. Resino. 2008. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. 46: 137-143.
3. Dominguez, S., G. Peytavin, M. Guiget, V. Calvez, D. Costaglioloa, F. Bricaire, T. Poynard, C. Katlama, and Y. Benhamou. 2005. The HEPADOSE study: evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV/HCV and HIV infected patients, abstr. WePp0305. Abstr. 3rd IAS Conf. HIV Pathogenesis Treatment.
4. Elbekai, R. H., H. M. Korashy, and A. O. El-Kadi. 2004. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr. Drug Metab. 5:157-167.
5. Figg, W. D., G. E. Dukes, H. R. Lesesne, S. W. Carson, S. S. Songer, J. F. Pritchard, D. J. Hermann, J. R. Powell, and L. J. Hak. 1995. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 15:693-700.
6. Ishak, K., A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, H. Denk, V. Desmet, G. Korb, R. N. MacSween, et al. 1995. Histological grading and staging of chronic hepatitis. J. Hepatol. 22:696-699.
7. Kappelhoff, B. S., F. van Leth, T. R. MacGregor, J. Lange, J. H. Beijnen, and A. D. Huitema. 2005. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. 10:145-155.
8. Kappelhoff, B. S., F. van Leth, P. A. Robinson, T. R. MacGregor, E. Baraldi, F. Montella, D. E. Uip, M. A. Thompson, D. B. Russell, J. M. Lange, J. H. Beijnen, and A. D. Huitema. 2005. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. 10:489-498.
9. Lamson, M., T. MacGregor, P. Riska, D. Erickson, P. Maxfield, L. Rowland, M. Gigliotti, P. Robinson, S. Azzam, and J. Keirns. 1999. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin. Pharmacol. Ther. 65:137.
10. Lamson, M. J., J. P. Sabo, T. R. MacGregor, J. W. Pav, L. Rowland, A. Hawi, M. Cappola, and P. Robinson. 1999. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm. Drug Dispos. 20:285-291.
11. Macias, J., V. Castellano, N. Merchante, R. B. Palacios, J. A. Mira, C. Saez, J. A. Garcia-Garcia, F. Lozano, J. M. Gomez-Mateos, and J. A. Pineda. 2004. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18:767-774. (Pubitemid 38535004)
12. Pav, J. W., L. S. Rowland, and D. J. Korpalski. 1999. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J. Pharm. Biomed. Anal. 20:91-98.
13. Riska, P., M. Lamson, T. MacGregor, J. Sabo, S. Hattox, J. Pav, and J. Keirns. 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27:895-901.
14. Rowland, L. S., T. R. MacGregor, S. J. Campbell, R. Jenkins, A. B. Pearsall, and J. P. Morris. 2007. Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 856:252-260. (Pubitemid 47302924)
15. Sokol, S. I., A. Cheng, W. H. Frishman, and C. S. Kaza. 2000. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J. Clin. Pharmacol. 40:11-30.
16. Veldekamp, A. I., R. P. G. van Heeswijk, J. A. Mulder, P. L. Meenhorst, R. M. W. Hoetelmans, J. M. A. Lange, and J. H. Beijnen. 2001. Limited sample strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther. Drug Monitor. 23:606-611.